These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1452223)

  • 1. Diversity and variation in human immunodeficiency virus: implications for immune control.
    Ramsay AJ
    Immunol Cell Biol; 1992 Jun; 70 ( Pt 3)():215-21. PubMed ID: 1452223
    [No Abstract]   [Full Text] [Related]  

  • 2. Genotypic and phenotypic variation of HIV-1: impact on AIDS pathogenesis and vaccination.
    Wolfs TF; Nara PL; Goudsmit J
    Chem Immunol; 1993; 56():1-33. PubMed ID: 8383980
    [No Abstract]   [Full Text] [Related]  

  • 3. Human immunodeficiency virus variants that escape cytotoxic T-cell recognition.
    Rowland-Jones SL; Phillips RE; Nixon DF; Gotch FM; Edwards JP; Ogunlesi AO; Elvin JG; Rothbard JA; Bangham CR; Rizza CR
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1353-4. PubMed ID: 1466955
    [No Abstract]   [Full Text] [Related]  

  • 4. How does the HIV escape cytotoxic T cell immunity?
    Phillips RE; McMichael AJ
    Chem Immunol; 1993; 56():150-64. PubMed ID: 7680867
    [No Abstract]   [Full Text] [Related]  

  • 5. [Role of the HIV-1 gp120 V1/V2 domains in the induction of neutralizing antibodies].
    Granados-González V; Piedrahita LD; Martínez M; Genin C; Riffard S; Urcuqui-Inchima S
    Enferm Infecc Microbiol Clin; 2009 Nov; 27(9):523-30. PubMed ID: 19409660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro inhibition of a variety of human immunodeficiency virus isolates by a broadly reactive, V3-directed heteroconjugate antibody.
    Higgins PJ; Paradis T; Potts BJ; White-Scharf ME; Rusche JR; Scott CF
    J Infect Dis; 1992 Jul; 166(1):198-202. PubMed ID: 1607697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seroreactivity of analogous antigenic epitopes in glycoprotein 120 expressed in HIV-1 subtypes A, B, C, and D.
    Pestano GA; Hosford KS; Spira AI; Riley J; Xie JM; Sewankambo N; Brown L; Ho DD; Boto WM
    AIDS Res Hum Retroviruses; 1995 May; 11(5):589-96. PubMed ID: 7576915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV T cell vaccines, the importance of clades.
    McMichael A; Mwau M; Hanke T
    Vaccine; 2002 May; 20(15):1918-21. PubMed ID: 11983245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide.
    Ota A; Tanaka-Taya K; Ueda S
    Hybridoma; 1999 Apr; 18(2):149-57. PubMed ID: 10380014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigenic variation in HIV.
    Putney SD; McKeating JA
    AIDS; 1990; 4 Suppl 1():S129-36. PubMed ID: 2152557
    [No Abstract]   [Full Text] [Related]  

  • 12. Induction of a strong HIV-specific CD8+ T cell response in mice using a fowlpox virus vector expressing an HIV-1 multi-CTL-epitope polypeptide.
    Vázquez Blomquist D; Green P; Laidlaw SM; Skinner MA; Borrow P; Duarte CA
    Viral Immunol; 2002; 15(2):337-56. PubMed ID: 12081016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of cross-reactive antigenic target regions for HIV type 1-specific antibody-dependent cellular cytotoxicity.
    Broliden K; Von Gegerfelt A; Persson C; Horal P; Svennerholm B; Wahren B; Björling E; Vahlne A
    AIDS Res Hum Retroviruses; 1996 Dec; 12(18):1699-702. PubMed ID: 8959246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral immune responses to homologous envelope peptides in vaccinees and lab workers infected with HIV.
    Pincus SH; Messer K
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1347. PubMed ID: 1466954
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-P30-52 monoclonal antibody cross-reacted to Env V3 and inhibited the viral multiplication of HIV-1-infected MT-4 cells.
    Ota A; Bautista AN; Yadav ML; Ueda S
    Hybridoma; 1999 Apr; 18(2):139-47. PubMed ID: 10380013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of autologous neutralization-resistant variants from preexisting human immunodeficiency virus (HIV) quasi species during virus rebound in HIV type 1-infected patients undergoing highly active antiretroviral therapy.
    Wang FX; Kimura T; Nishihara K; Yoshimura K; Koito A; Matsushita S
    J Infect Dis; 2002 Mar; 185(5):608-17. PubMed ID: 11865417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV. Escape artist par excellence.
    Cohen J
    Science; 2003 Mar; 299(5612):1505-8. PubMed ID: 12624245
    [No Abstract]   [Full Text] [Related]  

  • 18. Preliminary results of V3 loop peptide-primary neutralizing domain conjugate phase 1 vaccine trail.
    Rubinstein A; Goldstein H; Pettoello-Mantovani M; Cryz SJ
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S149-53. PubMed ID: 7865291
    [No Abstract]   [Full Text] [Related]  

  • 19. The immunopathogenesis of HIV infection.
    Rosenberg ZF; Fauci AS
    Adv Immunol; 1989; 47():377-431. PubMed ID: 2573256
    [No Abstract]   [Full Text] [Related]  

  • 20. HIV glycosylation: what does it portend?
    Myers G; Lenroot R
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1459-60. PubMed ID: 1466982
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.